Tin tức & Cập nhật

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.

Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.